<?xml version='1.0' encoding='utf-8'?>
<document id="17108809"><sentence text="In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms." /><sentence text="Genetic variation of the human ABCB1 (P-glycoprotein; MDR1 gene product) efflux transporter is strongly suggested as a determinant factor governing the pharmacokinetics of diverse drugs and xenobiotics" /><sentence text=" Despite various efforts to associate polymorphisms in ABCB1 to actual clinical effect and transport function, information is still inconsistent or even controversial" /><sentence text="" /><sentence text="Using membrane vesicle preparation from ABCB1-expressing HighFive insect cells, we report here that saturation kinectic parameters of the frequently occurring ABCB1 triallelic variants 893Ser (exon 21, 2677T) and 893Thr (2677A) were considerably different from wild-type 893Ala (2677G), despite similar protein expression levels" /><sentence text=" Of importance were significant differences in transport capacities between the tested 893Ala/Ser/Thr variants" /><sentence text=" In comparison with 893Ala, maximal transport rates for vincristine of 893Ser and 893Thr increased 50% and three-fold, respectively"><entity charOffset="56-67" id="DDI-PubMed.17108809.s7.e0" text="vincristine" /></sentence><sentence text=" Cis-inhibition by digoxin, didanosine or fexofenadine was least pronounced in 893Ser, whereas no genotype differences could be observed using verapamil"><entity charOffset="19-26" id="DDI-PubMed.17108809.s8.e0" text="digoxin" /><entity charOffset="28-38" id="DDI-PubMed.17108809.s8.e1" text="didanosine" /><entity charOffset="42-54" id="DDI-PubMed.17108809.s8.e2" text="fexofenadine" /><entity charOffset="143-152" id="DDI-PubMed.17108809.s8.e3" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.17108809.s8.e0" e2="DDI-PubMed.17108809.s8.e0" /><pair ddi="false" e1="DDI-PubMed.17108809.s8.e0" e2="DDI-PubMed.17108809.s8.e1" /><pair ddi="false" e1="DDI-PubMed.17108809.s8.e0" e2="DDI-PubMed.17108809.s8.e2" /><pair ddi="false" e1="DDI-PubMed.17108809.s8.e0" e2="DDI-PubMed.17108809.s8.e3" /><pair ddi="false" e1="DDI-PubMed.17108809.s8.e1" e2="DDI-PubMed.17108809.s8.e1" /><pair ddi="false" e1="DDI-PubMed.17108809.s8.e1" e2="DDI-PubMed.17108809.s8.e2" /><pair ddi="false" e1="DDI-PubMed.17108809.s8.e1" e2="DDI-PubMed.17108809.s8.e3" /><pair ddi="false" e1="DDI-PubMed.17108809.s8.e2" e2="DDI-PubMed.17108809.s8.e2" /><pair ddi="false" e1="DDI-PubMed.17108809.s8.e2" e2="DDI-PubMed.17108809.s8.e3" /></sentence><sentence text="" /><sentence text="These results suggest an influence of ABCB1-893 triallelic variants on transport function and drug-drug interaction, which might be most pronounced in 893Thr" /><sentence text=" Furthermore, some of the mechanisms of 2677G/T/A-based haplotype-associated alterations in ABCB1 activity may have been unveiled" /><sentence text="" /></document>